Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a developer of mitral heart valve replacements.

CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs.

A few days after leaving Insmed to take up an “employment opportunity on the West Coast”, Paul Streck has popped up at migraine specialist Alder.

The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials.

A University of Chicago teams has shown that a derivative of the hypertension drug Wytensin can protect myelin in animal models of multiple sclerosis.

Proteus Digital Health launched a smart chemotherapy pill that aims to help oncologists track effectiveness and adherence in their cancer patients.

Alzheimer’s drug developer Alzheon has pulled plans for a public listing on the Nasdaq for the second time in nine months.

Shares in the nanocap biotech shot up more than 100% in premarket trading before falling away somewhat as people dug deeper into the data.